Artiva Biotherapeutics posts updated Phase 2a AlloNK plus rituximab data in refractory rheumatoid arthritis at ACR 2026

• Artiva Biotherapeutics flagged updated Phase 2a basket-trial results for AlloNK with rituximab at ACR Convergence 2026.
• Data will be presented in November, covering at least 20 refractory rheumatoid arthritis patients with six months of follow-up.
• Additional updates will include Sjögren disease and systemic sclerosis cohorts, extending the readout across multiple immune-mediated indications.
• Posters will highlight robust clinical responses, deep B-cell depletion, consistent tolerability, positioning the program against CAR T benchmarks.
• A separate registry analysis will be presented to frame low response rates in heavily pretreated rheumatoid arthritis, supporting Phase 3 trial rationale.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artiva Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610020905PRIMZONEFULLFEED9838689) on October 02, 2026, and is solely responsible for the information contained therein.